Health Catalyst stock trades near lows as small-cap sentiment weakens

Published on 09/19/2026 at 10:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Health Catalyst stock is highlighted in a September 18, 2026 small-cap screen with a price around USD 1.79 and a low valuation. Recent quarterly figures show revenue growth but ongoing losses, giving investors a mixed picture for the data analytics specialist.

HCAT, US42226A1079, Illustration mit AI erstellt.

Health Catalyst Inc. stock (ISIN US42226A1079) remains under pressure, with the Nasdaq-listed shares recently changing hands at about USD 1.79 as of September 18, 2026, keeping the company among the lower-valued healthcare data analytics names in the small-cap universe. On that date, the stock was singled out in a small-cap review that noted its modest valuation despite a challenging earnings profile.

Small-cap screen puts valuation in focus

The latest catalyst for Health Catalyst stock comes from a small-cap assessment published on September 18, 2026, which pointed out that the shares trade at roughly USD 1.79 and about 0.6 times forward price-to-sales, a level that reflects both the company’s growth ambitions and investor caution. According to Yahoo Finance on September 18, 2026, Health Catalyst appears in a list of small-cap names analysts currently avoid, largely because profitability has yet to catch up with the revenue base.

This valuation snapshot matters because it gives investors a concrete benchmark: at USD 1.79 per share and 0.6 times forward price-to-sales, the market is assigning only a limited premium to Health Catalyst’s data and analytics platform compared with expected revenues. For context, that forward multiple is significantly below the typical 3.0 to 5.0 times range often seen for profitable software and analytics companies of similar size, underscoring the discount that accompanies Health Catalyst’s loss-making status.

Recent revenue growth contrasts with ongoing losses

Beyond the small-cap screen, the most recent quarterly figures show that Health Catalyst continues to grow its top line while still reporting net losses, a pattern that shapes sentiment around the stock. In its latest reported quarter for fiscal 2026, revenue increased compared with the prior-year period, highlighting ongoing demand for the company’s data warehousing, analytics, and services offerings to hospitals and health systems. At the same time, the company remained loss-making on a net basis, reflecting investments in product development and sales capacity that have yet to fully translate into bottom-line profitability.

Historically, Health Catalyst has reported double-digit percentage revenue growth, but the pace has moderated somewhat as the company matures and focuses on driving more efficient growth. In a prior fiscal year comparison, revenue stood at a higher level than in earlier years while operating margins remained negative, illustrating the trade-off the company has made between expansion and profitability. For investors, this gap between revenue growth and net income remains a central issue: the latest quarter’s loss, while narrower than in some earlier periods, still means that the company must eventually show a clear path to sustained positive earnings to justify even a modest valuation multiple.

The company’s management has previously emphasized improving adjusted EBITDA and cash flow, aiming to narrow losses over time. In recent results, adjusted EBITDA moved closer to breakeven compared with a larger deficit in the prior year, signaling some operational progress. However, with net loss still present in the latest figures, Health Catalyst’s ability to convert revenue into profit is not yet proven, a fact that feeds directly into the cautious view expressed by external commentators.

Risk profile and small-cap environment

The small-cap context is another factor weighing on Health Catalyst stock. Small-cap healthcare and technology names have generally faced higher volatility and tighter market liquidity in 2026, as risk appetite has shifted toward larger, profitable issuers. Against that backdrop, a company trading at USD 1.79 with a low forward price-to-sales multiple may appear attractive from a pure valuation standpoint, but only if investors believe that revenue growth will translate into positive earnings.

In the assessment published on September 18, 2026, Health Catalyst was classified among small caps that analysts currently avoid, which suggests that, despite revenue expansion, the perceived risk-adjusted return does not yet pass the bar set by that particular framework. According to Yahoo Finance, the cautious stance is driven by both company-specific factors and the tougher environment for unprofitable growth stocks.

For shareholders, the quantified comparison between Health Catalyst’s forward price-to-sales ratio of 0.6 and the higher multiples typically associated with profitable analytics peers highlights the market’s skepticism. The discount effectively prices in the risk that the company’s loss profile could persist longer than expected, which would require continued external funding or cash resources and could limit upside in the absence of a clear profitability timeline.

Stock price remains near recent lows

On the market side, Health Catalyst stock’s level around USD 1.79 as of September 18, 2026, places it close to the lower end of its trading range over the past year, even though the precise 52-week high and low were not detailed in the latest small-cap article. The modest absolute price underscores the sensitivity of the shares to even small percentage moves: a change of USD 0.18, for example, would already represent a 10 percent swing at this level, illustrating the volatility typical of small-cap names with limited liquidity.

In this environment, any fresh data point on margins, cash burn, or contract wins can move Health Catalyst stock noticeably, given the low base. If the company manages to turn its revenue growth into sustained positive earnings, the current forward price-to-sales ratio of 0.6 suggests room for re-rating toward levels more in line with profitable peers. Conversely, if losses widen again or revenue growth slows, the discount could persist or deepen further, keeping the shares anchored near the recent lows.

Price snapshot and investor takeaway

Health Catalyst stock is quoted on Nasdaq, and the reference price of about USD 1.79 as of September 18, 2026, reflects the last completed trading day before publication. At that level, the company’s market capitalization is relatively low for a healthcare data analytics provider, reinforcing its small-cap status and the importance of each quarterly report for reshaping investor expectations.